25 October 2022: Original Paper
Risk Factors for Polyomavirus, Cytomegalovirus, and Viruria Co-Infection for Follow-Up of Renal Transplant Patients
Ho Trung Hieu 1ABCDEFG* , Bui Tien Sy 2ACEFDOI: 10.12659/AOT.937771
Ann Transplant 2022; 27:e937771
Table 1 Characteristics of renal transplant recipients.
| Characteristic | Total patients (n=81) | Patients in VS groups (n=25) | Patients in VC groups (n=56) | p-value |
|---|---|---|---|---|
| Gender, male (%) | 62 (76.54) | 18 (72.0) | 44 (78.57) | |
| Age (years), mean±SD | 40.91±12.02 | 38.42±12.58 | 41.84±12.18 | |
| Etiology of End-Stage Renal Disease (%) | ||||
| Glomerulonephritis | 58 (71.6) | 17 (68.0) | 41 (73.21) | |
| Diabetes | 6 (7.41) | 2 (8.0) | 4 (7.14) | |
| Hypertension | 10 (12.35) | 4 (16.0) | 6 (10.71) | |
| Others | 6 (7.41) | 1 (1.12) | 5 (5.62) | |
| Type of renal replacement therapy (%) | ||||
| No renal replacement therapy | 10 (12.34) | 3 (12.0) | 7 (12.5) | |
| Hemodialysis | 69 (85.19) | 20 (80.0) | 49 (87.5) | |
| Peritoneal dialysis | 2 (2.47) | 2 (8.0) | – | |
| Time of RRT (months), mean±SD | 45.76±5.18 | 39.87±58.37 | 21.47±27.55 | * |
| Time of follow up after RTx | 28.84±19.78 | 20.57±12.45 | 33.27±21.38 | * |
| Donor source, Deceased (%) | 3 (3.7) | – | 3 (5.4) | ** |
| Frequency in charge due to clinical manifestations | ||||
| No in-charge | 60 (74.07) | 18 (72.0) | 42 (75.0) | |
| 1 time | 11 (13.58) | 4 (16.0) | 7 (12.5) | |
| 2 times and above | 10 (12.35) | 3 (12.0) | 7 (12.5) | |
| Creatine | ||||
| Baseline | 113.10±44.89 | 107.08±36.72 | 115.36±50.11 | |
| End-line | 106.70±76.89 | 95.58±22.73 | 109.97±94.93 | |
| Estimated glomerular filtration rate | *** | |||
| Baseline | 68.51±22.47 | 76.42±25.00 | 67.09±23.12 | |
| End-line | 75.56±22.43 | 81.82±19.84 | 75.18±23.09 | |
| Immunosuppresive therapy | ||||
| Tacrolimus (n, %) | 79 (97.53) | 24 (96.0) | 55 (98.21) | |
| Tacrolimus dose (mg/day), mean±SD | 5.48±3.47 | 5.25±3.50 | 5.08±3.17 | * |
| Tacrolimus trough level (ng/mL), mean±SD | 7.36±2.92 | 7.19±2.84 | 7.02±2.88 | * |
| MMF, (n,%) | 74 (91.36) | 23 (92.0) | 51 (91.07) | ** |
| MMF dose (mg/day), mean±SD | 1430.66±264.83 | 1409.84±260.71 | 1370.19±208.96 | * |
| Prednisolone (mg/day), mean±SD | 9.37±42.80 | 9±0.58 | 6±2.37 | |
| Myfortics (n,%) | 6 (7.41) | 1 (4.0) | 5 (8.93) | ** |
| Cyclosporine (n,%) | 1 (1.23) | 1 (1.79) | ||
| Combine tacrolimus+MMF+prednisolone | 73 (90.12) | 23 (92.0) | 50 (89.29) | |
| Induction therapy | ||||
| ATG (n, %) | 8 (9.88) | 1 (4.0) | 7 (12.5) | |
| Basiliximab (n, %) | 64 (79.01) | 22 (88.0) | 42 (75.0) | |
| Time until viremia, mean±SD | 9.47±15.28 | 7.07±7.48 | 10.49±17.55 | |
| * p-value of T-test; ** p-value of Chi-square test; *** p-value of Pair T-test. ATG – anti-human thymocyte globulin; MMF – mycophenolate mofetil; RTx – renal transplantation. | ||||